Pseudoexfoliation syndrome, a systemic disorder with ocular manifestations

Elhawy, Eman; Kamthan, Gautam; Dong, Cecilia Q.; Danias, John

doi:10.1186/1479-7364-6-22

Cited by 110 publications

(93 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several mechanisms of pseudoexfoliation material formation are possible, but a molecular background is more frequently suggested (30,(33)(34)(35). Oxidative stress is believed to contribute to the pathogenesis of many diseases.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical analysis of microsomal glutathione S-transferase 1 and clusterin expression in lens epithelial cells of patients with pseudoexfoliation syndrome

Stafiej

Hałas‐Wiśniewska

Izdebska

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Pseudoexfoliation syndrome (PEX) is an age-associated, sight disorder affecting elastic fibers in the eye and visceral organs but its exact etiology remains unknown. The purpose of the current study was to determine the morphology and ultrastructure of lens epithelial cells (LECs), and to use immunohistochemistry to examine localization of microsomal glutathione S-transferase 1 (MGST1) and clusterin. Anterior lens capsules were obtained from 24 patients (13 PEX and 11 controls) who underwent phacoemulsification. Immunohistochemistry was performed, using antibodies against MGST1 and clusterin, to determine their expression. The morphology and ultrastructure of LECs were evaluated by light and transmission electron microscopy, respectively. The PEX LECs were characterized by significantly lower MGST1 (P= 0.0001) and clusterin expression (P= 0.0005) compared with the control group patients. PEX LECs were also observed to have significantly increased thickness compared with the control group patients (P= 0.0002). The current findings suggest that low MGST1 and clusterin expression levels may be an early clinical indicator of PEX, and that oxidative stress may serve an important role, but that the specific etiology of this disease has yet to be revealed.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunohistochemical analysis of microsomal glutathione S-transferase 1 and clusterin expression in lens epithelial cells of patients with pseudoexfoliation syndrome

Stafiej

Hałas‐Wiśniewska

Izdebska

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Nađeni su: heparin i hondroitin sulfat proteoglikani, laminin, entaktin, nidogen, fibronektin i amiloid P protein; kolagen tipa IV je ograničen na mikrofibrilarni sloj između površine kapsule i tipičnog PEX materijala (24). Dodatno, prisustvo epitopa elastina ukazuje da je PEX materijal multikomponentna ekspresija poremećaja u sintezi ekstraćelijskog matriksa, uključujući inkorporaciju osnovnih nekolagenih komponenti bazalne membrane (25,26). Ekstenzivna obeleženost materijala na hondroitin sulfat pokazuje preveliku produkciju i abnormalni metabolizam glikozaminoglikana kao osnovne promene u ovom poremećaju (27).…”

Section: Diskusijaunclassified

Pseudoexfoliation glaucoma: Always actual problem in ophthalmology

Vasović¹,

Markovic²

2018

Medicinski podmladak

View full text Add to dashboard Cite

Introduction: Pseudoexfoliation (PEX) syndrome is not only an ocular disease but also a general disorder that involves the abnormal production and disposal of extracellular matrix material in intra-and extraocular tissues. Intraocular pressure (IOP) of the pseudoexfoliative eyes is higher than IOP of the nonpseudoexfoliative eyes which leads to more severe eye damage during longer period of time. Glaucoma in the pseudoexfoliation syndrome has been shown to have a more serious clinical course than in primary open-angle glaucoma. Aim: The aim of our study was to determine the presence and frequency of capsular glaucoma compared to other types of glaucoma among patients examined in one month period and in total number of glaucoma operated patients during last year. Materials and methods: Our study involved 105 patients examined and diagnosed in November 2016 and 346 glaucoma patients operated between January and October 2016 at Clinic for eye diseases, Clinical Centre of Serbia. Methods used in examination and monitoring of patients were: biomicroscopy, applanation tonometry, computerized perimetry, ophthalmoscopy, gonioscopy and Heidelberg Retinal Tomography II. Results: Although the frequency of capsular glaucoma in our sample was more common in women 14 (13.4 %) compared to men 11 (10.4 %), statistically significant difference related to sex was not observed (p = 0.352). Binocular expression was 3.7 times more often than monocular in women and 1.7 times in men. Among glaucoma operated patients, capsular glaucoma was found in 94 (27.2 %) cases, which leads to conclusion that every fourth patient operated last year had this type of glaucoma. Conclusion: Based on the results of our study it can be concluded that capsular glaucoma, as the most important ocular manifestation of PEX syndrome, shows high frequency in our population. Careful clinical examination should be performed in patients over the age of 50 due to the importance of early recognition and appropriate management of pseudoexfoliative material in the eye.

show abstract

“…DNA sequence variants in several complement proteins found in drusen are associated with increased disease risk [94][95][96][97], but no variants in CLU have yet been associated with disease. [98]. CLU is a component of pseudoexfoliation deposits [99][100][101], and a deficiency of CLU has been suggested as a factor in accumulation of deposits [102], which appears to lead to complement activation [103].…”

Section: Age-related Macular Degeneration -This Disease Is Characterimentioning

confidence: 99%

Clusterin in the eye: An old dog with new tricks at the ocular surface

Fini

Bauskar

Jeong

et al. 2016

Experimental Eye Research

View full text Add to dashboard Cite

, M. R. (2016). Clusterin in the eye: an old dog with new tricks at the ocular surface. Experimental Eye Research, Clusterin in the eye: an old dog with new tricks at the ocular surface AbstractThe multifunctional protein clusterin (CLU) was first described in 1983 as a secreted glycoprotein present in ram rete testis fluid that enhanced aggregation ('clustering') of a variety of cells in vitro. It was also independently discovered in a number of other systems. By the early 1990s, CLU was known under many names and its expression had been demonstrated throughout the body, including in the eye. Its homeostatic activities in proteostasis, cytoprotection, and anti-inflammation have been well documented, however its roles in health and disease are still not well understood. CLU is prominent at fluid-tissue interfaces, and in 1996 it was demonstrated to be the most highly expressed transcript in the human cornea, the protein product being localized to the apical layers of the mucosal epithelia of the cornea and conjunctiva. CLU protein is also present in human tears. Using a preclinical mouse model for desiccating stress that mimics human dry eye disease, the authors recently demonstrated that CLU prevents and ameliorates ocular surface barrier disruption by a remarkable sealing mechanism dependent on attainment of a critical all-or-none concentration in the tears. When the CLU level drops below the critical all-or-none threshold, the barrier becomes vulnerable to desiccating stress. CLU binds selectively to the ocular surface subjected to desiccating stress in vivo, and in vitro to LGALS3 (galectin-3), a key barrier component. Positioned in this way, CLU not only physically seals the ocular surface barrier, but it also protects the barrier cells and prevents further damage to barrier structure. CLU depletion from the ocular surface epithelia is seen in a variety of inflammatory conditions in humans and mice that lead to squamous metaplasia and a keratinized epithelium. This suggests that CLU might have a specific role in maintaining mucosal epithelial differentiation, an idea that can now be tested using the mouse model for desiccating stress. Most excitingly, the new findings suggest that CLU could serve as a novel biotherapeutic for dry eye disease. Competing Interests: US patent 9,241,974 B2 entitled "Clusterin pharmaceuticals and treatment methods using the same" (inventors: MEF and SJ), assigned to the University of Southern California, is connected with this work. MEF holds a management position with Proteris Biotech, Inc., Pasadena, CA, which is developing Protearin for dry eye based on clusterin. MRW declares that he has no competing interests. Page 3 of 65 AbstractThe multifunctional protein clusterin (CLU) was first described in 1983 as a secreted glycoprotein present in ram rete testis fluid that enhanced aggregation ('clustering') of a variety of cells in vitro. It was also independently discovered in a number of other systems. By the early 1990s, CLU was known under many names and its expression had bee...

show abstract

Pseudoexfoliation syndrome, a systemic disorder with ocular manifestations

Cited by 110 publications

References 63 publications

Immunohistochemical analysis of microsomal glutathione S-transferase 1 and clusterin expression in lens epithelial cells of patients with pseudoexfoliation syndrome

Immunohistochemical analysis of microsomal glutathione S-transferase 1 and clusterin expression in lens epithelial cells of patients with pseudoexfoliation syndrome

Pseudoexfoliation glaucoma: Always actual problem in ophthalmology

Clusterin in the eye: An old dog with new tricks at the ocular surface

Contact Info

Product

Resources

About